A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

• Status: Recruiting
• Trial end date: 2026-02-11
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Docetaxel

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed locally advanced or metastatic NSCLC, urothelial carcinoma or HNSCC

• Progressed after at least 1 line of treatment and no more than 3 lines of treatment

• At least one measurable lesion as defined by RECIST version 1.1

• ECOG Performance Status 0 or 1

• Adequate Bone Marrow Function

• Adequate Renal Function

• Adequate Liver Function

• Resolved acute effects of any prior therapy

Exclusion Criteria:

• Known active uncontrolled or symptomatic CNS metastases.

• Major surgery, radiation therapy, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry.

• Active, uncontrolled infection, including COVID-19

• Known or suspected hypersensitivity to PF-06939999

• Inability to consume or absorb study drug